These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25837799)

  • 1. Can EGFR mutations in plasma or serum be predictive markers of non-small-cell lung cancer? A meta-analysis.
    Wu Y; Liu H; Shi X; Song Y
    Lung Cancer; 2015 Jun; 88(3):246-53. PubMed ID: 25837799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
    Cui C; Sun X; Zhang J; Han D; Gu J
    J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
    He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
    Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: a meta-analysis.
    Zhang Q; Dai HH; Dong HY; Sun CT; Yang Z; Han JQ
    Lung Cancer; 2014 Sep; 85(3):339-45. PubMed ID: 25043903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue or blood: which is more suitable for detection of EGFR mutations in non-small cell lung cancer?
    Biaoxue R; Shuanying Y
    Int J Biol Markers; 2018 Jan; 33(1):40-48. PubMed ID: 29552976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer.
    Zhu G; Ye X; Dong Z; Lu YC; Sun Y; Liu Y; McCormack R; Gu Y; Liu X
    J Mol Diagn; 2015 May; 17(3):265-72. PubMed ID: 25769900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR mutations in non-small-cell lung cancer among smokers and non-smokers: a meta-analysis.
    Ren JH; He WS; Yan GL; Jin M; Yang KY; Wu G
    Environ Mol Mutagen; 2012 Jan; 53(1):78-82. PubMed ID: 22223435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis.
    Li Z; Zhang Y; Bao W; Jiang C
    Target Oncol; 2014 Dec; 9(4):381-8. PubMed ID: 24623059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.
    Yeo CD; Kim JW; Kim KH; Ha JH; Rhee CK; Kim SJ; Kim YK; Park CK; Lee SH; Park MS; Yim HW
    Lung Cancer; 2013 Aug; 81(2):207-12. PubMed ID: 23726527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.
    Luo J; Shen L; Zheng D
    Sci Rep; 2014 Sep; 4():6269. PubMed ID: 25201768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
    Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
    Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis.
    Qiu M; Wang J; Xu Y; Ding X; Li M; Jiang F; Xu L; Yin R
    Cancer Epidemiol Biomarkers Prev; 2015 Jan; 24(1):206-12. PubMed ID: 25339418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.
    Zhao X; Han RB; Zhao J; Wang J; Yang F; Zhong W; Zhang L; Li LY; Wang MZ
    Respiration; 2013; 85(2):119-25. PubMed ID: 22797485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
    He C; Liu M; Zhou C; Zhang J; Ouyang M; Zhong N; Xu J
    Int J Cancer; 2009 Nov; 125(10):2393-9. PubMed ID: 19530244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The detection by denaturing high performance liquid chromatography of epidermal growth factor receptor mutation in tissue and peripheral blood from patients with advanced non-small cell lung cancer].
    Bai H; Zhao J; Wang SH; An TT; Wang X; Wu MN; Duan JC; Yang L; Guo QZ; Liu NH; Wang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Dec; 31(12):891-6. PubMed ID: 19134404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients.
    Yam I; Lam DC; Chan K; Chung-Man Ho J; Ip M; Lam WK; Chan TK; Chan V
    J Thorac Oncol; 2012 Jul; 7(7):1131-40. PubMed ID: 22610259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study identifying a potential plasma biomarker for determining EGFR mutations in exons 19 or 21 in lung cancer patients.
    Pamungkas AD; Medriano CA; Sim E; Lee S; Park YH
    Mol Med Rep; 2017 Jun; 15(6):4155-4161. PubMed ID: 28487968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.
    Masago K; Fujita S; Togashi Y; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Sakamori Y; Mio T; Mishima M
    Oncol Rep; 2011 Oct; 26(4):795-803. PubMed ID: 21805046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.